Medtronic received information via literature regarding outcomes of aortic and mitral valve surgery for rheumatic heart disease in (b)(6).All data were collected from a (b)(6) center between 2009 and 2017.The study population included 240 patients (predominantly female, mean age 19 years).Multiple manufacturer¿s devices were implanted in the study population.Among all patients eight were implanted with a medtronic porcine bioprosthetic valve (n=2) or mechanical valve (n=6) in either the aortic or mitral valve position.No model names or other unique device identifier numbers were provided.Among all bioprosthetic and mechanical valve patients, adverse events included: stroke, major bleeding requiring intervention, endocarditis, svd, new onset atrial fibrillation (afib), and wound infection.Based on the available information medtronic product may have been associated with the adverse event(s).No additional adverse patient effects or product performance issues were reported.
|